Antivirals
- PDF / 170,181 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 39 Downloads / 149 Views
1 S
Treatment failure: 4 case reports A study described 4 men aged 51–74 years, who exhibited treatment failure with daclatasvir, glecaprevir/pibrentasvir, ledipasvir/ sofosbuvir, peginterferon, ribavirin or sofosbuvir/velpatasvir while being treated for hepatitis C virus (HCV) infections [dosages and routes not stated]. Patient 1: A 52-year-old man, who had been infected with human immunodeficiency virus (HIV; CDC stage A1) infection for 35 years, had been receiving anti-retroviral therapy comprising abacavir, raltegravir and lamivudine. He subsequently developed HCV infection and started receiving anti-HCV therapy with dalactasvir and peginterferon [pegylated interferon], along with ribavirin. However, a virological breakthrough was noted at week 4 (treatment failure), which was further confirmed at week 6. Hence, his anti-HCV therapy was discontinued. Patient 2: A 55-year-old man, who had diabetes and HIV (CDC stage B1) infection for 23 years, for which he had been receiving antiretroviral therapy comprising darunavir, cobicistat and lamivudine, was subsequently diagnosed with HCV infection. Hence, he started receiving anti-HCV therapy with peginterferon along with sofsbuvir/velpatasvir and ribavirin. However, a relapse was observed at week 12 post treatment. Patient 3: A 74-year-old man, who had been infected with HCV, started receiving anti-HCV therapy with glecaprevir/pibrentasvir. However, a relapse was observed at week 12 post treatment. Patient 4: A 51-year-old man, who had diabetes and HIV (CDC stage B2) infection for 33 years, developed HCV coinfection along with cirrhosis. He received his first round of antiretroviral therapy with darunavir/ritonavir and dolutegravir; however, he was later switched to dolutegravir/rilpivirine along with emtricitabine/tenofovir alefenamide with undetectable HIV RNA. For the HCV infection, he was initially treated with peginterferon and ribavirin; however, no response was noted. He was subsequently treated with sofosbuvir/ledipasvir along with ribavirin; however, a relapse was observed at week 4 post treatment. Caputo V, et al. Detection of low-level HCV variants in DAA treated patients: Comparison amongst three different NGS data analysis protocols. Virology Journal 17: 13 Jul 803514742 2020. Available from: URL: http://doi.org/10.1186/s12985-020-01381-3
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
